IQVIA Holdings and Boehringer Ingelheim have entered into a long‑term partnership that will deploy IQVIA’s Data‑as‑a‑Service (DaaS+) platform across 59 countries to accelerate Boehringer’s global commercial data harmonization and transformation efforts.
The collaboration expands IQVIA’s commercial analytics footprint and reinforces its strategy to deepen relationships with top‑tier pharmaceutical clients while growing recurring data‑services revenue. For Boehringer, the partnership supports its digitalization focus, improves real‑world evidence generation, and enhances decision‑making for its commercial teams.
Justin Gale, Boehringer’s Global Head of Data Excellence, said the DaaS+ platform would drive significant efficiencies by enabling seamless ingestion of global commercial data sets into a unified platform. Tom Baker, IQVIA’s Senior Vice President of Global Data, Technologies and Advisory Services, added that the collaboration will help Boehringer harness IQVIA’s innovative solution to create a global data foundation and accelerate the path toward an AI‑powered analytics future.
The DaaS+ platform is powered by IQVIA’s Human Data Science Cloud and leverages its Global Data Model. The partnership aligns with the broader industry trend of leveraging advanced data analytics and AI in life sciences, marking a strategic win for IQVIA and a notable customer acquisition that signals continued demand for integrated analytics capabilities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.